EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Histopathologic Insights and Treatment Outcomes in PD-1 and PDL-1 Cutaneous Immune-Related Adverse Events: A Case Series

Amanda Rodriguez Orengo, Alicia Mizes, Irina Lerman, Abigail I. Franco, Mary Gail Mercurio, Paul Blackcloud

International Journal of Medical Students · 16.03.2026 · 14 (1) · 19-23

DOI: 10.5195/ijms.2026.3588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Students, online erschienen am 16.03.2026. Verfasst von Amanda Rodriguez Orengo und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs), including therapies targeting anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PDL-1), are highly effective for treating various malignancies, but are often associated with immune-related adverse events (irAEs). Among these, cutaneous irAEs are the most prevalent, affecting about half of patients and varying widely in severity. irAEs can impact quality of life and lead to treatment discontinuation. Managing these side effects effectively is essential to allow continuation of therapy without compromising its efficacy.

Methods

Retrospective case series.

Results

We present three patients who developed severe cutaneous irAEs: two with pembrolizumab-induced lichenoid dermatitis and one with atezolizumab-induced psoriasiform rash. Initial treatment was guided by histopathologic findings, leading to the use of dupilumab, an interleukin-4 receptor (IL-4Ra) monoclonal antibody, in all three cases. While two patients achieved full resolution with dupilumab, the third case, which progressed to a clinically psoriasiform morphology, was later treated with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, resulting in significant improvement.

Conclusion

These cases highlight the critical role of combining histopathologic and clinical insights to customize treatment approaches. Both dupilumab and apremilast are steroid-sparing options with favorable safety profiles and offer effective alternatives to systemic corticosteroids without compromising the efficacy of ICIs.

Zitieren

APA

Orengo, A. R., Mizes, A., Lerman, I., Franco, A. I., Mercurio, M. G., & Blackcloud, P. (2026). Histopathologic Insights and Treatment Outcomes in PD-1 and PDL-1 Cutaneous Immune-Related Adverse Events: A Case Series. International Journal of Medical Students, 14(1), 19-23. https://doi.org/10.5195/ijms.2026.3588

Vancouver

Orengo AR, Mizes A, Lerman I, Franco AI, Mercurio MG, Blackcloud P. Histopathologic Insights and Treatment Outcomes in PD-1 and PDL-1 Cutaneous Immune-Related Adverse Events: A Case Series. International Journal of Medical Students. 2026;14(1):19-23. doi:10.5195/ijms.2026.3588

BibTeX
@article{Orengo2026,
  author = {Orengo, Amanda Rodriguez and Mizes, Alicia and Lerman, Irina and Franco, Abigail I. and Mercurio, Mary Gail and Blackcloud, Paul},
  title = {Histopathologic Insights and Treatment Outcomes in PD-1 and PDL-1 Cutaneous Immune-Related Adverse Events: A Case Series},
  journal = {International Journal of Medical Students},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {19--23},
  doi = {10.5195/ijms.2026.3588}
}
Kostenlos starten →